A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1 Meeting Abstract

  

Authors:	Baselga, J.; Tamura, K.; Yamashita, T.; Modi, S.; Tokunaga, E.; Ito, Y.; Iwata, H.; Charif, M.; Lee, C. C.; Sugihara, M.; Jikoh, T.; Andre, F.
Abstract Title:	A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1
Meeting Title:	54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	36
Issue:	15 Suppl.
Meeting Dates:	2018 Jun 1-5
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2018-05-20
Start Page:	59s
Language:	English
ACCESSION:	WOS:000442916007519
DOI:	10.1200/JCO.2018.36.15_suppl.TPS1102
PROVIDER:	wos
Notes:	Meeting Abstract: TPS1102 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/169414